Abstract：OBJECTIVE: Some research has shown that Newcastle disease virus (NDV) is effective in the treatment of various tumors, including transferred melanoma and well differentiated renal cell carcinoma. This study aimed to evaluate the effect of NDV against human acute monocytic leukemia SHI-1 cells in vitro and in vivo. METHODS: In vitro, the density and morphologic changes between wild SHI-1 cells (control) and NDV-infected SHI-1 cells were observed. MTT assay was utilized to observe the effect of NDV on the proliferation of SHI-1 cells. In vivo, the effect of NDV on the tumor inhibition was assessed using SHI-1 xenografts subcutaneously established in CD-1 nude mice. NDV was given by intra-tumor injections, and the tumor inhibition rate and toxic effects were evaluated. RESULTS: In the control group, the SHI-1 cells were observed using an inverted microscope to be regular in morphology and intensive in distribution. In the NDV-infected group, the SHI-1 cells were irregular and sparsate, and the aggregate and fused cells were common. MTT assay showed that the proliferation of SHI-1 cells were significantly inhibited by NDV at different concentrations (P<0.01) and in a time- and concentration-dependent manner. The tumor inhibition rate in the NDV group was 84.7%, which was significantly higher than that in the control group (P<0.01). No toxic effects were observed in the nude mice. CONCLUSIONS: NDV can suppress the proliferation of human acute monocytic leukemic cells both in vitro and in vivo. The safety of NDV is reliable.
WANG Ya-Jun,SONG Chun,LI Xiao-Hui et al. Roles of Newcastle disease virus in human acute monocytic leukemia in vitro and in vivo[J]. CJCP, 2011, 13(2): 149-152.
［1］Schirrmacher V, Haas C, Bonifer R,Ahlert T,Gerhards R,Ertel C.Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus［J］.Gene Ther, 1999, 6(1): 63-73.
［2］Vigil A, Park MS, Martinez O,Chua MA,Xiao S,Cros JF,et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus［J］. Cancer Res, 2007, 67(17): 8285-8292.
［6］Wendtner CM, Kofler DM, Mayr C, Bund D, Hallek M. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors［J］.Leuk Lymphoma, 2004, 45(5): 897-904.
［9］Fabian Z, Csatary CM, Szeberenyi J, Csatary LK.p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines［J］. J Virol, 2007,81(6): 2817-2830.
［10］Estevez C, King D, Seal B, Yu Q. Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone［J］. Virus Res, 2007, 129(2): 182-190.
［11］Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration［J］. Cancer Lett, 2001,172 (1):27-36.
［12］Puhler F, Willuda J, Puhlmann J, Mumberg D, Romer-Oberdorfer A, Beier R. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes［J］.Gene Ther, 2008, 15(5): 371-383.
